Hikma Pharmaceuticals PLC
LSE:HIK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 722
2 083
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC
Other Current Liabilities
Hikma Pharmaceuticals PLC
Other Current Liabilities Peer Comparison
GSK
AZN
VRNA
INDV
DPH
Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Other Current Liabilities
$624m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Other Current Liabilities
£2.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Other Current Liabilities
$2.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-2%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Other Current Liabilities
$2m
|
CAGR 3-Years
50%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Other Current Liabilities
$192m
|
CAGR 3-Years
26%
|
CAGR 5-Years
19%
|
CAGR 10-Years
-6%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Other Current Liabilities
£15.6m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-13%
|
See Also
What is Hikma Pharmaceuticals PLC's Other Current Liabilities?
Other Current Liabilities
624m
USD
Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Other Current Liabilities amounts to 624m USD.
What is Hikma Pharmaceuticals PLC's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
12%
Over the last year, the Other Current Liabilities growth was 28%. The average annual Other Current Liabilities growth rates for Hikma Pharmaceuticals PLC have been 15% over the past three years , 13% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet
